🇺🇸 FDA

Drug profile · INN

nusinersen sodium

SPINRAZA INITIAL APPROVAL

FDA: approved PMDA: approved
US status
approved
Patents linked
0
News articles
0

Quick answer

nusinersen sodium (SPINRAZA INITIAL APPROVAL) is an FDA-listed pharmaceutical active ingredient. Route of administration: intrathecal. Current US regulatory status: approved.

Key facts

INN nusinersen sodium
Brand SPINRAZA INITIAL APPROVAL
Route INTRATHECAL
Formulation SOLUTION

Frequently asked questions

What is nusinersen sodium?

nusinersen sodium (SPINRAZA INITIAL APPROVAL) is an FDA-listed pharmaceutical active ingredient. Route of administration: intrathecal. Current US regulatory status: approved.

What is the brand name for nusinersen sodium?

SPINRAZA INITIAL APPROVAL is a marketed brand name for nusinersen sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of nusinersen sodium?

nusinersen sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.